<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg"/></p>
<p>Strive 的诉讼是制药行业与配药药房之间激烈斗争的最新一例。oleschwander via Shutterstock.com。</p>
<p>一家美国配药药房起诉了礼来和诺和诺德，指控他们阻碍患者获得复合减肥药物的机会。</p>
<p>Strive 配药药房表示，这些在胰高血糖素样肽-1 受体激动剂（GLP-1RA）市场占主导地位的制药公司正在进行 “协调努力，以压制竞争并限制患者获得合法复合 GLP-1RA 药物的机会”。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Eli Lilly and Co 的 LY-3556050</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>NPVM: Novo Nordisk AS 的 LAI-287 + Semaglutide</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现有效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>这起 诉讼 于美国德克萨斯州西区地方法院提起，指控礼来和诺和诺德利用其市场主导地位破坏配药药房行业。文件强调了制药公司与远程医疗提供商签署的独家合作伙伴关系，以便与配药行业竞争。它还指出，礼来和诺和诺德在过去一年内建立了自己的在线药房，通过直接面向消费者（DTC）现金渠道以折扣价提供品牌 GLP-1RA。</p>
<p>通过这些联盟、在线 DTC 平台和明显的营销策略，Strive 指控礼来和诺和诺德的行为 “非法限制了竞争，并直接伤害了美国的 GLP-1RA 患者。”</p>
<p>诺和诺德的一位发言人告诉《制药技术》： “本次诉讼中的指控毫无依据，我们将积极在法庭上进行辩护。诺和诺德始终致力于与监管机构和执法部门合作，确保患者能够获得安全、有效且经过 FDA 批准的治疗选择，并保护患者免受未获批准的仿制药物的重大安全风险。”</p>
<p>礼来的一位发言人告诉《制药技术》： “Strive 的诉讼在事实和法律上都是错误的，试图将焦点转移到其自身行为上。礼来已起诉 Strive，指控其将未经批准的大规模复合产品宣传为临床证明和 “个性化” 的，FDA 和联邦法院现在都表示这些说法是虚假和误导的。我们期待在法庭上回应 Strive。”</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报的信息</p>
<p>Strive 的诉讼是制药行业与 配药药房之间激烈斗争的最新一例。 复合药物是根据处方定制的非品牌药物，含有与市场上药物相同的活性成分，例如诺和诺德的 semaglutide 或礼来的 tirzepatide。根据美国食品药品监督管理局（FDA）的规定，商业可用药物短缺是允许复合生产的标准之一。</p>
<p>在 2024 年，礼来的 Mounjaro/Zepbound 和诺和诺德的 Wegovy/Ozempic 短缺期间，复合 GLP-1RA 的使用激增。对许多患者来说，这些版本的一个额外好处是，当时它们的价格远低于品牌药物。然而，随着供应链的稳定，FDA 不再允许复合 GLP-1RA 的生产。这是尽管外包设施协会提起的诉讼，最终 被美国地区法官驳回。FDA 专员 Marty Makary宣布了对非法 GLP-1RA 复合药物的打击 在 2025 年 10 月。</p>
<p>诺和诺德在 2025 年中与 Hims &amp; Hers 建立了合作关系，但在几天后 终止了该合作，指控该远程医疗平台 “未能遵守法律”。</p>
<p>礼来和诺和诺德已经对几家在线供应商、健康水疗中心和远程医疗平台提起诉讼，指控它们制造其品牌的 GLP-1 受体激动剂的复合版本。</p>
<p>在本周的摩根大通医疗会议上，诺和诺德的首席执行官 Maziar Mike Doustdar 估计，大约有 150 万美国患者正在使用其 GLP-1 受体激动剂的复合版本。他指责这些复合药物制造商针对那些更看重价格的消费者。复合药物行业的存在是为了提供个性化的药物版本，而不是更便宜的替代品。</p>

<p>Strive Compounding Pharmacy 已对礼来和诺和诺德提起诉讼，指控这两家公司在 GLP-1RA 市场上压制竞争，以限制患者获得复方药物的机会。诉讼称，礼来和诺和诺德利用其市场主导地位，通过独家合作伙伴关系和自有在线药房来削弱复方药房的业务。两家公司均否认这些指控，声称 Strive 的主张毫无依据，并表示他们致力于患者安全。此案突显了制药行业与复方药房之间持续的紧张关系</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/01/shutterstock_2386001631-430x241.jpg"/></p>
<p>Strive’s lawsuit is the latest in a fierce battle between the pharma industry and compounding pharmacies. oleschwander via Shutterstock.com.</p>
<div class="lb-trans"><p>Strive 的诉讼是制药行业与配药药房之间激烈斗争的最新一例。oleschwander via Shutterstock.com。</p>
</div><p>An American compounding pharmacy has sued Eli Lilly and Novo Nordisk for allegedly stifling patient access to compounded weight loss medications.</p>
<div class="lb-trans"><p>一家美国配药药房起诉了礼来和诺和诺德，指控他们阻碍患者获得复合减肥药物的机会。</p>
</div><p>Strive Compounding Pharmacy said that the drugmakers, who dominate the glucagon-like peptide-1 receptor agonist (GLP-1RA) market, are engaging in a “coordinated effort to suppress competition and limit patient access to lawful compounded GLP-1RA medications”.</p>
<div class="lb-trans"><p>Strive 配药药房表示，这些在胰高血糖素样肽-1 受体激动剂（GLP-1RA）市场占主导地位的制药公司正在进行 “协调努力，以压制竞争并限制患者获得合法复合 GLP-1RA 药物的机会”。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Eli Lilly and Co's LY-3556050</h4>
<div class="lb-trans"><h4>NPVM: Eli Lilly and Co 的 LY-3556050</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>NPVM: Novo Nordisk AS's LAI-287 + Semaglutide</h4>
<div class="lb-trans"><h4>NPVM: Novo Nordisk AS 的 LAI-287 + Semaglutide</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现有效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The lawsuit, filed in the United States District Court for the Western District of Texas, alleges that Lilly and Novo used their dominant market positions to undermine the compounding pharmacy industry. The document highlights exclusive partnerships that the pharma companies signed with telehealth providers in efforts to compete with the compounding sector. It also points to Lilly and Novo establishing their own online pharmacies in the past year, which offer branded GLP-1RAs via direct-to-consumer (DTC) cash channels at a discounted price.</p>
<div class="lb-trans"><p>这起 诉讼 于美国德克萨斯州西区地方法院提起，指控礼来和诺和诺德利用其市场主导地位破坏配药药房行业。文件强调了制药公司与远程医疗提供商签署的独家合作伙伴关系，以便与配药行业竞争。它还指出，礼来和诺和诺德在过去一年内建立了自己的在线药房，通过直接面向消费者（DTC）现金渠道以折扣价提供品牌 GLP-1RA。</p>
</div><p>Through these alliances, online DTC platforms, and apparent marketing strategies, Strive alleges that Lilly and Novo’s conduct “unlawfully restricted competition and directly harmed GLP-1RA patients in the United States.”</p>
<div class="lb-trans"><p>通过这些联盟、在线 DTC 平台和明显的营销策略，Strive 指控礼来和诺和诺德的行为 “非法限制了竞争，并直接伤害了美国的 GLP-1RA 患者。”</p>
</div><p>A Novo spokesperson told <em>Pharmaceutical Technology</em>: “The claims in this litigation are without merit, and we will vigorously defend against them in court. Novo Nordisk remains committed to working alongside regulators and law enforcement to ensure that patients have access to safe, effective, and FDA-approved treatment options and to protect patients from unapproved knockoff drugs that pose significant risks to patient safety.”</p>
<div class="lb-trans"><p>诺和诺德的一位发言人告诉《制药技术》： “本次诉讼中的指控毫无依据，我们将积极在法庭上进行辩护。诺和诺德始终致力于与监管机构和执法部门合作，确保患者能够获得安全、有效且经过 FDA 批准的治疗选择，并保护患者免受未获批准的仿制药物的重大安全风险。”</p>
</div><p>A Lilly spokesperson told <em>Pharmaceutical Technology</em>: “Strive’s lawsuit is wrong, on both the facts and law, and an attempt to shift focus away from its own conduct. Lilly sued Strive for advertising its unapproved, mass-compounded products as clinically proven and “personalized,” and both FDA and a federal court have now said that those kinds of statements are false and misleading. We look forward to responding to Strive in court.”</p>
<div class="lb-trans"><p>礼来的一位发言人告诉《制药技术》： “Strive 的诉讼在事实和法律上都是错误的，试图将焦点转移到其自身行为上。礼来已起诉 Strive，指控其将未经批准的大规模复合产品宣传为临床证明和 “个性化” 的，FDA 和联邦法院现在都表示这些说法是虚假和误导的。我们期待在法庭上回应 Strive。”</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报的信息</p>
</div><p>Strive’s lawsuit is the latest in a fierce battle between the pharma industry and compounding pharmacies. Compounded drugs are custom-made and unbranded medications that contain the same active ingredient as a marketed drug, such as Novo’s semaglutide or Lilly’s tirzepatide, pursuant to a prescription. A shortage of a commercially available drug is one of the criteria that allows compounded production, as per US Food and Drug Administration (FDA) regulation.</p>
<div class="lb-trans"><p>Strive 的诉讼是制药行业与 配药药房之间激烈斗争的最新一例。 复合药物是根据处方定制的非品牌药物，含有与市场上药物相同的活性成分，例如诺和诺德的 semaglutide 或礼来的 tirzepatide。根据美国食品药品监督管理局（FDA）的规定，商业可用药物短缺是允许复合生产的标准之一。</p>
</div><p>The use of compounded GLP-1RAs surged during shortages of Lilly’s Mounjaro/Zepbound and Novo’s Wegovy/Ozempic in 2024. An added benefit for many patients was that these versions were far cheaper than the branded counterparts at the time.  However, with supply chains now stabilised, the FDA no longer allows compounded GLP-1RA production. This was despite a lawsuit by the Outsourcing Facilities Association, which ultimately ended up being dismissed by a US district judge. FDA commissioner Marty Makary announced a clamp down on illegal GLP-1RA compounders in October 2025.</p>
<div class="lb-trans"><p>在 2024 年，礼来的 Mounjaro/Zepbound 和诺和诺德的 Wegovy/Ozempic 短缺期间，复合 GLP-1RA 的使用激增。对许多患者来说，这些版本的一个额外好处是，当时它们的价格远低于品牌药物。然而，随着供应链的稳定，FDA 不再允许复合 GLP-1RA 的生产。这是尽管外包设施协会提起的诉讼，最终 被美国地区法官驳回。FDA 专员 Marty Makary宣布了对非法 GLP-1RA 复合药物的打击 在 2025 年 10 月。</p>
</div><p>Novo entered into a partnership with Hims &amp; Hers in mid-2025 but terminated it just days later after accusing the telehealth platform of “failing to adhere to the law”.</p>
<div class="lb-trans"><p>诺和诺德在 2025 年中与 Hims &amp; Hers 建立了合作关系，但在几天后 终止了该合作，指控该远程医疗平台 “未能遵守法律”。</p>
</div><p>Lilly and Novo have already taken several online vendors, wellness spas, and telehealth platforms to court for making compounded versions of their branded GLP-1RAs.</p>
<div class="lb-trans"><p>礼来和诺和诺德已经对几家在线供应商、健康水疗中心和远程医疗平台提起诉讼，指控它们制造其品牌的 GLP-1 受体激动剂的复合版本。</p>
</div><p>Speaking at the J.P. Morgan Healthcare Conference this week, Novo’s CEO, Maziar Mike Doustdar, estimated that around 1.5 million US patients are using compounded versions of its GLP-1RAs. He accused compounders of targeting consumers who prioritised price. The compounded sector exists to provide personalised versions of drugs, rather than cheaper alternatives.</p>
<div class="lb-trans"><p>在本周的摩根大通医疗会议上，诺和诺德的首席执行官 Maziar Mike Doustdar 估计，大约有 150 万美国患者正在使用其 GLP-1 受体激动剂的复合版本。他指责这些复合药物制造商针对那些更看重价格的消费者。复合药物行业的存在是为了提供个性化的药物版本，而不是更便宜的替代品。</p>
</div>

Compounder sues Lilly and Novo for suppressing GLP-1RA competition

Pharmaceutical Technology

2 倍做多纳斯达克生物技术 ETF - ProShares

Defiance Daily Target 2X Short LLY ETF

2 倍做多 LLY ETF - Defiance

2 倍做多 LLY ETF - Direxion

礼来

1 倍做空 LLY ETF - Direxion

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

诺和诺德公司

基因改革 ETF - ARK

2 倍做多 NVO ETF - Defiance

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - Vanguard

医疗业 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

美国制药 ETF - iShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

Compounder 公司起诉礼来和诺和诺德公司，指控他们压制 GLP-1RA 的市场竞争